NELLY OKERE: Open Payments
NPI 1326580705 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,249 in 107 payments from 14 companies in 2025. Trend: 2023 $1,621 · 2024 $2,087 · 2025 $2,249
Food & beverage: $2,239Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $565 |
| Otsuka America Pharmaceutical, Inc. | 12 | $377 |
| Alkermes, Inc. | 8 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $258 |
| E.R. Squibb & Sons, L.L.C. | 11 | $229 |
| Vanda Pharmaceuticals Inc. | 9 | $163 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Lundbeck LLC | 3 | $83 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
Products named: VRAYLAR, CAPLYTA, COBENFY, ARISTADA, REXULTI, ABILIFY MAINTENA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
